Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IBM Divests Watson Health Assets To Focus On Cloud And AI Businesses

Executive Summary

Investment firm Francisco Partners will acquire IBM’s Watson Health’s data and analytics assets – including Micromedex, MarketScan, and Clinical Development – for an undisclosed price.

You may also be interested in...



Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.

IBM Enriches Health Data Mine With Truven

IBM says its Watson Health division will boast “the largest and most diverse” repositories of health-related data, after sealing a $2.6bn deal to acquire Truven Health Analytics. The deal, IBM’s fourth healthcare data-related acquisition in less than 12 months, will bring more than 8,500 new clients, including US federal and state government agencies, employers, health plans, hospitals, clinicians and life sciences companies, to Watson Health’s portfolio.

Digital Health News In Brief

FTC clamps down on acne apps

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel